How a lack of leadership in HIV prevention is failing those at risk of infection in the UK (and beyond) In July 2012, the US Food and Drug Administration took a landmark decision when it approved the use of the antiviral Truvada for the prevention
The New York Times started a debate on Pre-Exposure Prophylaxis (PrEP) for the prevention of HIV infection by asking five prominent researchers and HIV advocates to discuss whether promoting the use of antiviral drugs was a good public health strategy, or if it will encourage more
Don’t we all know that popping pills is not the solution to all our problems? The writer reflects on his and other’s assumptions about the role of biomedical interventions in the control of the HIV epidemic. This blog’s title mirrors that of Jake Sobo’s “Why
2011, the year of PrEP. In less than 18 months 6 clinical trials investigating the potential use of HIV antiretrovirals (ARV) for the prevention of HIV acquisition have rocked the HIV prevention world. First it was the South African CAPRISA announcing in July 2010
Closure of oral Tenofovir arm in VOICE Pre-Exposure Prophylaxis trial: PrEP as a “niche intervention”?
The Microbicides Trial Network (MTN) announced yesterday that its VOICE (Vaginal and Oral Interventions to Control the Epidemic, MTN003) HIV Pre-Exposure Prophylaxis (PrEP) prevention study will discontinue the daily oral tenofovir arm of the trial. The decision follows an interim review of the trial’s data